OBIO - NASDAQ

Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.

OBIOยทNASDAQ

$3.86

-0.52%
HealthcareBiotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$231.14M
EPS-1.1100
P/E Ratio-3.48
Earnings Date08/11/2026
Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. Fair Value Envelope

OBIO ยท NASDAQ

Our analysis suggests that OBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.86, this represents a potential HIDDEN relative to our calculated worth for Orchestra BioMed Holdings, Inc..

HIDDEN
Intrinsic Value
Current Price: $3.86

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$376.7M
+ Cash & Equivalents$34.7M
Firm Value-$342.0M
- Debt$1.7M
Equity Value-$343.7M
/ Shares Outstanding53,955,085B
DCF Value-$6
OVERVALUED BY 265%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$50.3M
-$51.7M
-$53.1M
-$54.6M
-$56.1M
-$57.6M
-$59.2M
-$60.8M
-$62.5M
-$64.2M
Maintenance CapEx
-$100.5K
-$103.2K
-$106.1K
-$109.0K
-$112.0K
-$115.0K
-$118.2K
-$121.4K
-$124.8K
-$128.2K
Owner Earnings
-$50.4M
-$51.8M
-$53.2M
-$54.7M
-$56.2M
-$57.7M
-$59.3M
-$60.9M
-$62.6M
-$64.3M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$46.7M
-$44.4M
-$42.2M
-$40.2M
-$38.2M
-$36.4M
-$34.6M
-$32.9M
-$31.3M
-$29.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your OBIO research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.